Family Medicine
Partner With Us
Advertisement
Conexiant chevron_right Family Medicine chevron_right Omalizumab Bests Oral Immunotherapy for Food Allergies
Conference News From the Journals AAAAI/WAO Joint Congress

Omalizumab Bests Oral Immunotherapy for Food Allergies

"These differences were largely driven by the high rate of adverse events leading to study discontinuation in the OIT-treated participants, despite receiving omalizumab treatment at the initiation of therapy."

Conexiant
article Full Article subject Summary summarize Notecard
  1. Omalizumab monotherapy demonstrated superior efficacy and safety compared to omalizumab-facilitated multi-allergen oral immunotherapy.
  2. Research presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress highlighted the effectiveness of omalizumab monotherapy in treating multi-food allergies.
  3. OmtMATCH Stage 2 trial showed that 36% of patients reached the goal of tolerance to ≥ 2,000 mg for all three trigger foods with omalizumab monotherapy.
  4. Omalizumab-treated patients experienced fewer adverse events and treatment discontinuations compared to those treated with oral immunotherapy.
  5. Serious adverse events occurred in 0% of patients receiving omalizumab compared to 30.5% in the oral immunotherapy group.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.